All In Biotech

Drug Trial Radar · NCT06875258

PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)

PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0, a Multicentre, Randomized Clinical Trial (PEHAB-II)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Jan 15, 2024

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Lead sponsor
The Netherlands Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Antoni van Leeuwenhoek Hospital; Viatris Inc.; Memidis Pharma
First posted
Mar 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PEHAB-II study is prospective, randomized trial designed to assess the effect of two different rehabilitation strategies on the recovery of erectile function in nerve sparing prostatectomy patients. The two rehabilitation strategies consist of 1)12 months daily doses of 100 mg Sildenafil combined with vacuum device (VED) therapy for 10 minutes a day, five times a week or 2) Standard of care: monotherapy with an on-demand dosage of 100mg Sildenafil. The study will be performed in multiple centers in the Netherlands.

Conditions

  • Erectile Dysfunction Following Radical Prostatectomy

Interventions

  • SildenafilDrug

    Taken daily or on demand. First two weeks dosage of 75mg to manage side effects. If side effects are bearable, dosage will be adjusted to 100mg

  • Erectile vacuum deviceDevice

    5 days a week, generating 5 erections per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Erectile function without toolsTime frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Canisius Wilhelmina Ziekenhuis

    Nijmegen, Gelderland, Netherlands · Not yet recruiting

  • Antoni van Leeuwenhoek hospital, Netherlands Cancer Institute

    Amsterdam, North Holland, Netherlands · Recruiting

  • Maasstad ziekenhuis

    Rotterdam, South Holland, Netherlands · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.